Study of a new drug for moderate to severe Crohn's disease
Part of Digestive system clinical trials.
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had Crohn's disease for at least 3 months, confirmed by a colonoscopy.
- Your Crohn's symptoms must be moderate to severe, with a score between 220 and 450 on a standard activity index.
- You must have previously tried and not responded well to at least one standard treatment, like steroids, immunosuppressants, or biologic drugs.
- You cannot have other types of colitis, active abscesses, or strictures blocking the intestine.
- You must not have had extensive bowel surgery or have a stoma.
- You must not have failed more than 3 different types of biologic or targeted therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This study tests a new medicine called SL-325, which may help reduce inflammation in the gut. It is for people with moderate to severe Crohn's disease who have not responded well to other treatments.
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Hear when a new Crohn's Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.